Summary of the Conference Call for Boya Bio-Pharmaceuticals Company Overview - **Company**: Boya Bio-Pharmaceuticals - **Industry**: Blood products and biopharmaceuticals Key Points Industry and Regulatory Changes - Starting January 2026, the value-added tax on blood products will increase from 3% to 13%, leading to a significant decline in the company's actual pre-tax prices and creating substantial uncertainty for 2026 performance. The company is currently seeking policy exemptions from the State Administration of Taxation [2][8] - The blood products industry is facing increased pressure from price controls and expanded procurement policies, which are expected to impact pricing and inventory levels [4][8] Financial Performance and Projections - In 2025, the company achieved a plasma collection volume of 662.31 tons, a 5% increase year-over-year, with Green Cross contributing 119.91 tons, reflecting a 10.46% growth [2][5] - The consolidated gross margin for 2025 is projected at 49.9%, a decrease of 14.8 percentage points, primarily due to the lower margin of Green Cross and overall industry price pressures [2][5] - The company anticipates that the new production process for Green Cross's immunoglobulin will enhance yield from 1,200-1,300 units/liter to levels comparable to Boya's standards [2][5] Research and Development - The company has accelerated its R&D pipeline, with approvals for 10% concentration immunoglobulin and human tetanus immunoglobulin, and clinical approval for PCC [2][10] - The company aims to expand its international sales, particularly in "Belt and Road" markets, with products currently in the registration phase in various countries [2][10] Strategic Focus and Business Segmentation - Boya is actively divesting non-blood product businesses, having completed the disposal of Boya New and is targeting the divestiture of Nanjing New Hundred by 2026 to focus entirely on blood products [2][14] - The company is implementing integrated management across its 21 plasma stations to enhance efficiency and reduce costs, particularly in key provinces like Jiangxi and Anhui [7][9] Market Competition and Challenges - The introduction of recombinant human albumin is not expected to pose a significant threat in the short term due to its higher costs and limited indications compared to human-derived products [3][13] - The company is exploring ways to manage the competition from imported albumin by discussing potential regulatory adjustments with national authorities [3][13] Future Outlook - The company is optimistic about its growth trajectory, aiming to exceed the industry average growth rate of approximately 5.5% in 2026 [2][5][9] - Despite the challenges posed by regulatory changes and market pressures, the company plans to enhance operational efficiency and maintain a focus on high-quality development through innovation and strategic marketing [17] Conclusion - Boya Bio-Pharmaceuticals is navigating a complex regulatory environment while focusing on growth in its core blood products business. The company is committed to improving operational efficiencies and expanding its market presence, particularly in international markets, while managing the challenges posed by increased taxation and competition.

Core Viewpoint - The domestic blood products industry is expected to maintain steady growth in the issuance of batches for albumin, intravenous immunoglobulin (IVIG), and fibrinogen by 2025, with an increase in the proportion of domestic albumin batch issuances compared to the previous year [1] Industry Summary - The issuance growth rate for factor VIII and prothrombin complex concentrate (PCC) is accelerating, while the issuance of rabies immunoglobulin and anti-rabies immunoglobulin is also showing good growth [1] - Due to centralized procurement and other factors, some domestic companies have adjusted the bidding prices for products like albumin and factor VIII, which is beneficial for increasing sales volume through price adjustments [1] - Companies are continuously advancing their research and development pipelines, focusing on recombinant products and new types of immunoglobulins, including chromatographic IVIG and subcutaneous immunoglobulin [1] - By 2026, the industry is advised to pay attention to the expansion of plasma stations, trends in industry mergers and acquisitions, and progress in new product development [1] - Companies that are at the forefront of the industry and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]

Core Viewpoint - China Resources Bohua Biopharmaceutical Group Co., Ltd. reported a revenue increase of 12.51% in the first half of 2025, driven by a focus on blood products and strategic business adjustments [2]. Group 1: Financial Performance - In the first half of 2025, the company achieved consolidated revenue of 1.008 billion yuan, an increase of 112 million yuan year-on-year, representing a growth rate of 12.51% [2]. - The company’s overall plasma collection volume reached 320.39 tons, reflecting a year-on-year growth of 7.2%, which is above the industry average [3]. Group 2: Business Strategy - The company is committed to deepening its focus on core blood product businesses and enhancing the comprehensive utilization of plasma [2]. - The marketing model has been dynamically adjusted, with successful outcomes in chronic disease management platform construction and strong market performance in PCC and factor VIII [2]. Group 3: Product Development and Innovation - The company successfully obtained approval for the clinical trial of subcutaneous immunoglobulin, which is expected to have a large market potential due to its advantages over intravenous administration [3]. - The 10% immunoglobulin product was approved for market launch in May 2025, with expectations for partial product approvals within the year [3]. Group 4: International Expansion - The company has achieved significant international milestones, including obtaining drug registration certificates in the Dominican Republic and GMP certificates in Turkey for its products [2]. Group 5: Market Conditions and Challenges - The company noted a slight price reduction in albumin due to market supply changes, while maintaining a balanced production and sales of core products [3]. - The company is actively applying for new plasma collection stations, although approval remains uncertain [3].

Financial Performance - In the first half of 2025, the company achieved a consolidated revenue of CNY 1.008 billion, an increase of CNY 112 million, representing a year-on-year growth of 12.51% [2][3] - The raw plasma collection volume increased by 7.2% year-on-year, surpassing the industry average growth rate [3][10] Product Development and Market Strategy - The company successfully obtained approval for the clinical trial of subcutaneous immunoglobulin (皮丙) in April 2025, positioning itself among the top three in the domestic market for this product [5][6] - The 10% intravenous immunoglobulin (静丙) was officially approved for market entry in May 2025, with a strong academic promotion strategy in place [7][15] - The company is focusing on enhancing its marketing strategies and academic promotion to address clinical pain points and ensure proper medication use [7][14] International Expansion - The company has made significant strides in international markets, obtaining drug registration certificates in the Dominican Republic and Turkey for its products [3][15] - The internationalization strategy includes targeting markets with regulatory systems similar to China's before advancing to stricter markets like Europe and the US [15] Supply Chain and Production - The company maintained a balanced production and sales for its core products, with inventory levels remaining reasonable [4] - The overall plasma collection volume reached 320.39 tons in the first half of 2025, with a year-on-year growth of 7.2% [10] Regulatory and Market Challenges - The company is adapting to the ongoing changes in the blood product procurement policies, which are gradually expanding in scope and variety [13][14] - The impact of the introduction of recombinant human albumin on the market is being monitored, as both recombinant and human-derived albumin play significant roles in clinical applications [12] Future Outlook - The company is committed to becoming a world-class blood product enterprise, focusing on core competencies and optimizing product structure [18] - Plans for expanding plasma collection stations are in place, although approvals from various government levels may introduce uncertainties [11]

Group 1 - The core viewpoint indicates that the blood products industry is expected to maintain steady growth in the first half of 2025, with a notable increase in the proportion of domestic albumin batch approvals compared to the previous year [1] - The approval batches for factor products such as factor VIII and fibrinogen are growing rapidly, reflecting companies' ongoing expansion of their factor product pipelines [1] - Companies are actively advancing research and development pipelines for recombinant products and new immunoglobulins, with several products already approved or under review for market launch [1] Group 2 - The blood products industry is anticipated to achieve overall steady growth in the second half of the year, driven by stabilizing product prices, increased plasma collection, and performance contributions from new products [1] - Companies that are industry leaders and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]

Group 1 - The core viewpoint is that the humanoid robot sector is expected to experience explosive growth in 2024, particularly in logistics scenarios transitioning from demo to customer trials in the second half of this year [1] - The overseas market is anticipated to be the first choice for logistics applications due to higher labor costs [1] - Companies with strong secondary development capabilities and leading core suppliers in commercialization progress are recommended for attention [1] Group 2 - The airport sector is highlighted as a key area for bottom-fishing opportunities, with international passenger flow recovery being a major focus [2] - A series of policies driving macroeconomic recovery and domestic consumption is expected to enhance the commercial segment's average transaction value by 2025 [2] - The revision of duty-free agreements and the progress of tax shop leasing require further monitoring, with limited downside potential for duty-free discount rates [2] Group 3 - The blood products industry is projected to maintain steady growth, with stable issuance of albumin and immunoglobulin products in the first half of 2025 [3] - The increase in domestic albumin issuance and rapid growth in factor products reflect ongoing expansion in product pipelines [3] - Companies positioned at the industry forefront, focusing on both organic growth and external integration to expand plasma station resources, are recommended for attention [3]

Group 1 - The core viewpoint indicates that the blood products industry is expected to maintain steady growth in the first half of 2025, with a notable increase in the proportion of domestic albumin batch approvals compared to the previous year [1] - The approval growth rate for factor products such as factor VIII and fibrinogen is accelerating, reflecting companies' ongoing expansion of their factor product pipelines [1] - Companies are actively advancing the research and development of recombinant products and new immunoglobulins, with several products already approved or under review for market launch [1] Group 2 - The overall blood products industry is projected to sustain steady growth in the second half of the year, driven by stabilizing product prices, increased plasma collection, and performance contributions from new products [1] - Companies that are industry leaders and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]

Core Insights - The blood products industry is expected to maintain steady growth in the first half of 2025, with a notable increase in the proportion of domestic albumin batch approvals compared to the previous year [1] - The rapid growth in batch approvals for factor products such as factor VIII and fibrinogen indicates ongoing expansion in the product pipeline by companies [1] - Continuous progress in the research and development of recombinant products and new immunoglobulins, including chromatographic intravenous immunoglobulin and subcutaneous immunoglobulin, has led to several products being approved or under review for market launch [1] - The industry is projected to benefit from stable product prices, increased plasma collection, and performance growth from new products in the second half of the year [1] - Companies positioned at the industry forefront are recommended for attention, particularly those that can expand plasma station resources through both organic growth and external integration [1]

Group 1 - The core viewpoint indicates that the blood products industry is expected to maintain steady growth in the first half of 2025, with a notable increase in the proportion of domestic albumin batch approvals compared to the previous year [1] - The approval growth rate for factor products such as factor VIII and fibrinogen is accelerating, reflecting companies' ongoing expansion of their factor product pipelines [1] - Companies are actively advancing the research and development of recombinant products and new immunoglobulins, with several products already approved or under review for market launch [1] Group 2 - The blood products industry is projected to achieve overall steady growth in the second half of the year, driven by stabilizing product prices, increased plasma collection, and performance contributions from new products [1] - It is recommended to focus on leading companies in the industry that are likely to continue expanding plasma station resources through both organic growth and external integration, ensuring sustained growth in blood product business [1]

Group 1: Company Strategy and Growth - The company will focus on its core business of blood products, enhancing plasma supply capacity and marketing management, while actively expanding into overseas markets and improving product R&D capabilities [1] - The company aims to increase annual production capacity to over 3,000 tons following the expansion of its subsidiary, with production expected to resume in June 2025 [2][3] - The company plans to achieve a sales expense ratio of under 10% and a management expense ratio of under 7% in 2025 [2] Group 2: Product Development and Market Position - The subsidiary Guangdong Shuanglin Jiuyin is expected to obtain listing approval in 2026, while the fourth-generation intravenous immunoglobulin is anticipated to receive approval in 2027 [2] - The company expects a more than 20% year-on-year increase in plasma output in 2025 due to expanded production capacity [3] - Currently, over 60% of albumin in the market is imported, indicating potential for domestic alternatives in the future [4] Group 3: Shareholder Engagement and Financial Management - The company will implement the 2024 dividend plan promptly after approval at the annual shareholders' meeting [2] - The major shareholder will continue to support the company's development and has initiated a share buyback plan [4] - The company has maintained a high dividend payout ratio for two consecutive years and plans to continue this trend [4]